![](/images/graphics-bg.png)
Natalizumab Treatment Modulates Peroxisome Proliferator-Activated Receptors Expression in Women with Multiple Sclerosis
Joint Authors
Chinetti-Gbaguidi, G.
Derudas, B.
Ferret-Sena, Véronique
Maia e Silva, Alexandra
Sena, Armando
Cavaleiro, Inês
Vale, José
Staels, Bart
Source
Issue
Vol. 2016, Issue 2016 (31 Dec. 2016), pp.1-5, 5 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2016-12-18
Country of Publication
Egypt
No. of Pages
5
Main Subjects
Abstract EN
Peroxisome Proliferator-Activated Receptors (PPAR) are transcription factors suggested to be involved in inflammatory lesions of autoimmune encephalomyelitis and multiple sclerosis (MS).
Our objective was to assess whether Natalizumab (NTZ) therapy is associated with alterations of PPAR expression in MS patients.
We analyzed gene expression of PPAR in peripheral blood mononuclear cells (PBMC) as well as blood inflammatory markers in women with MS previously medicated with first-line immunomodulators (baseline) and after NTZ therapy.
No differences in PPARα, PPARβ/δ, PPARγ, and CD36 mRNA expression were found in PBMC between patients under baseline and healthy controls.
At three months, NTZ increased PPARβ/δ mRNA (p=0.009) in comparison to baseline, while mRNA expression of PPARγ and CD36 (a well-known PPAR target gene) was lower in comparison to healthy controls (p=0.026 and p=0.028, resp.).
Although these trends of alterations remain after six months of therapy, the results were not statistically significant.
Osteopontin levels were elevated in patients (p=0.002) and did not change during the follow-up period of NTZ treatment.
These results suggest that PPAR-mediated processes may contribute to the mechanisms of action of NTZ therapy.
American Psychological Association (APA)
Ferret-Sena, Véronique& Maia e Silva, Alexandra& Sena, Armando& Cavaleiro, Inês& Vale, José& Derudas, B.…[et al.]. 2016. Natalizumab Treatment Modulates Peroxisome Proliferator-Activated Receptors Expression in Women with Multiple Sclerosis. PPAR Research،Vol. 2016, no. 2016, pp.1-5.
https://search.emarefa.net/detail/BIM-1115327
Modern Language Association (MLA)
Ferret-Sena, Véronique…[et al.]. Natalizumab Treatment Modulates Peroxisome Proliferator-Activated Receptors Expression in Women with Multiple Sclerosis. PPAR Research No. 2016 (2016), pp.1-5.
https://search.emarefa.net/detail/BIM-1115327
American Medical Association (AMA)
Ferret-Sena, Véronique& Maia e Silva, Alexandra& Sena, Armando& Cavaleiro, Inês& Vale, José& Derudas, B.…[et al.]. Natalizumab Treatment Modulates Peroxisome Proliferator-Activated Receptors Expression in Women with Multiple Sclerosis. PPAR Research. 2016. Vol. 2016, no. 2016, pp.1-5.
https://search.emarefa.net/detail/BIM-1115327
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1115327